There is growing evidence that combinations of antiangiogenic proteins with other antineoplastic treatments such as chemo-or radiotherapy and suicide genes-mediated tumor cytotoxicity lead to synergistic effects. In the present work, we tested the activity of two non-replicative herpes simplex virus (HSV)-1-based vectors, encoding human endostatinHangiostatin or endostatinHkringle5 fusion proteins in combination with HSV-1 thymidine kinase (TK) molecule, on endothelial cells (ECs) and Lewis lung carcinoma (LLC) cells. We observed a significant reduction of the in vitro growth, migration and tube formation by primary ECs upon direct infection with the two recombinant vectors or cultivation with conditioned media obtained from the vector-infected LLC cells. Moreover, direct cytotoxic effect of HSV-1 TK on both LLC and ECs was demonstrated. We then tested the vectors in vivo in two experimental settings, that is, LLC tumor growth or establishment, in C57BL/6 mice. The treatment of pre-established subcutaneous tumors with the recombinant vectors with ganciclovir (GCV) induced a significant reduction of tumor growth rate, while the in vitro infection of LLC cells with the antiangiogenic vectors before their implantation in mice flanks, either in presence or absence of GCV, completely abolished the tumor establishment.
Introduction
Formation of new blood vessels from pre-existing ones is a complex process requiring migration, proliferation and differentiation of endothelial cells (ECs). Tumor-induced neoangiogenesis plays a key role in solid tumor growth and onset of distant metastases. Endostatin, angiostatin and kringle5 are some of the most efficient and best characterized endogenous angiogenesis inhibitors described so far. Endostatin, the 20 kDa C-terminal fragment of proteolytic cleavage of collagen XVIII, has been shown to inhibit EC proliferation 1 and also to interfere with the vascular endothelial growth factor (VEGF)-mediated angiogenic pathway. 2 The 38 kDa angiostatin molecule, comprising the first four kringle domains of plasminogen, is a potent inducer of EC apoptosis 3 and has also been reported to reduce vascular density and branching. 4 The fifth kringle domain of plasminogen, a small protein of 15 kDa named kringle5, is a potent inhibitor of EC migration 5 and of basic fibroblast growth factor (bFGF)-induced neoangiogenesis in vitro. 6 Systemic administration of recombinant endostatin or angiostatin, although capable of producing significant inhibition of tumor growth in animal models, has not been successful in clinical trials so far [7] [8] [9] [10] owing to their short systemic half-life and high costs of production and purification. Moreover, highly vascularized, invasive tumors necessitate combinations of different angiogenesis inhibitors to control their growth, rather than single antiangiogenic molecules, even at elevated doses. 11 A highly advantageous combined antiangiogenic therapy should thus possibly contain inhibitors of different steps of a particular proangiogenic pathway, or inhibitors of different pathways. Live recombinant viral vectors are considered to be attractive candidates for gene delivery directly into the tumors and their surrounding stromal tissue, generating high in situ expression of therapeutic molecules. Multiple immediate early gene-deleted non-replicative herpes simplex virus (HSV)-1 vectors are characterized by high efficiency of transduction of several different host species and cell types, both dividing and non-dividing, including various tumor as well as ECs. [12] [13] [14] [15] [16] Furthermore, these vectors are able to accommodate a total of 50 kbp of independently regulated expression cassettes in different sites of a unique vector backbone. Two or more therapeutic molecules, acting additively or synergistically, can thus be expressed at comparable levels by cells transduced with a combination vector, which is clearly an advantage in comparison with co-administration of two or more vectors encoding a single transgene and also in comparison with coexpression of two molecules, separated by internal ribosome entry site (IRES) sequences, by a unique vector. Another important feature of HSV-1-based vectors is their capacity to express the autologous tk gene, encoding the thymidine kinase (TK) enzyme, a well-characterized suicide gene, widely used in gene therapy of different experimental tumors, [17] [18] [19] and which has already been tested in clinical trials. [20] [21] [22] Another advantage of the use of TK/GCV (ganciclovir) system is that it is capable of killing both vector-transduced and neighboring cells, owing to the bystander effect. 23 In the present study, we evaluated the activity of two different non-replicative HSV-1-based vectors, named T0endoHangio and T0endoHkringle5, encoding human endostatinHangiostatin or endostatinHkringle5 fusion proteins as well as autologous HSV-1 TK enzyme, on EC and Lewis lung carcinoma (LLC) tumor cells. We observed a considerable reduction of the in vitro growth, migration and tube formation by primary ECs upon direct infection with T0endoHangio and T0endoHkrin-gle5 vectors or following their cultivation with conditioned media obtained from the vector-infected LLC tumor cells. Direct cytotoxic effect of HSV-1 TK on both LLC cells and ECs was also demonstrated. We also tested T0endoHangio and T0endoHkringle5 vectors in vivo in two different experimental settings, that is, LLC tumor growth or establishment, in C57BL/6 murine model. The treatment of pre-established subcutaneous tumors by local administration of recombinant vectors in presence of GCV induced a significant reduction of tumor growth rate but was not able to completely arrest it, except when TK-encoding vector was used and GCV administration was started 24 h later. However, the in vitro infection of LLC cells with T0endoHangio and T0endoHkringle5 before their implantation in mice flanks, either in presence or absence of GCV treatment, was able to completely abolish the tumor establishment. TK-expressing vectorinfected LLC cells also failed to establish tumors, but only in GCV-treated mice.
Materials and methods
Cell lines and culture conditions Vero (ATCC, Rockville, MD), Vero-derived 7b cells 24 and LLC cells (ATCC) were maintained in high glucose Dulbecco's modified Eagle's medium (Euroclone, Pero, Milan, Italy) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum. The 7b cells were subjected monthly to 1 week long selection with 1 mg/ml G418 (Roche, Monza, Milan, Italy). Primary human umbilical vein endothelial cells (HUVECs; Istituto Zooprofilattico Lombardia ed Emilia Romagna, Brescia, Italy) were cultured in Endothelial growth culture medium-2 medium (Clonetics, San Diego, CA), in collagen-coated tissue culture flasks (BD, Milan, Italy), subcultured 1:3 once a week and used up to passage 7.
Plasmids and recombinant vectors construction
The endostatin-angiostatin and endostatin-kringle5 cDNAs for construction of T0endoHangio and T0en-doHkringle5 HSV-1 vectors were obtained from pGT64 and pGT60 plasmids (InvivoGen, San Diego, CA), respectively. These fusion genes encode 20 amino acids from the human interleukin-2 secretion signal, amino acids H 1291 to K 1473 from the human collagen XVIII gene (endostatin) and a 8-amino-acid elastin linker motif VPGVGTNS. Human plasminogen-derived amino acids P 466 to D 566 are present in endoHkringle5, and amino acids V 98 to V 462 in endoHangio. The cDNAs were subcloned in the pcDNA3.1 shuttle plasmid (InVitroGen, Milan, Italy) under the transcriptional control of the human cytomegalovirus (HCMV) immediate early promoter and were then inserted in a previously described plasmid, p41, containing the HSV-1 UL41 locus flanking sequences (HSV-1 map positions 93 858-92 230 and  91 631-90 145 bp) . 24 The expression cassettes of the two transgenes were introduced in place of the previously inserted Escherichia coli lacZ cassette of the triple mutant vector T0Z by homologous recombination, using a previously described highly efficient protocol 25 based on the standard calcium phosphate co-transfection of 5 mg of viral DNA and 1 mg of the recombinant plasmids. To purify transgene-encoding vectors, three rounds of limiting dilution were performed. The presence of transgenes in recombinant viral genomes was confirmed by Southern blot analysis after each limiting dilution.
Viral stock production HSV-1 stocks were prepared by infecting the complementing 7b cells at a multiplicity of infection (MOI) of 0.05. Infected cells were harvested when a 100% cytopathic effect was reached. Cells were separated from the supernatants, subjected to three cycles of freezethawing, sonicated and centrifuged at 3000 r.p.m. The resulting supernatant was added to the one obtained in the previous step and centrifuged at 20 000 r.p.m. to recover the virus. Viral particles were further purified by density gradient centrifugation (OptiPrep, Axis-Shield, Norway). Virus stocks were stored at À801C. All stocks were titrated on 7b cells; final titers averaged from 1 Â 10 8 to 8 Â 10 8 plaque-forming units (PFU)/ml.
Western blotting
Vero (1 Â 10 6 ) and LLC cells were infected with the recombinant vectors at MOI 2.0. Following a 1 h adsorption period, the infected cells were plated in six-well plates and incubated for 24, 48 and 72 h at 371C in 5% CO 2 . The samples were collected and submitted to electrophoresis on 12% sodium dodecyl sulfate-polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad, Milan, Italy) and incubated with a rabbit polyclonal antibody specific for human endostatin (Oncogene Research Products, Boston, USA) diluted 1:1000, followed by a mouse anti-rabbit IgG horseradish peroxidase-linked secondary antibody at 1:2500 dilution. Immunocomplexes were detected by ECL detection kit (Amersham Biosciences, Cologno Monzese, Milan, Italy).
Cytotoxicity assay LLC and HUVEC cells were infected in suspension for 1 h at MOI 1.0 and dispensed into 96-well flat-bottom plates at a concentration of 2.5 Â 10 3 and 3.0 Â 10 3 LLC or HUVEC, respectively. Prodrug GCV (Sigma, Milan, Italy) was then added at a concentration of 5 mg/ml and cells were incubated at 371C in 5% CO 2 . Cell viability was evaluated at different time points (1-3 days and 1-4 days for LLC and HUVEC, respectively) with the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. 26 Absorbance values were read at 570 nm by a microtiter plate spectrophotometer (Multiscan EX 1.1; Labsystems, Milan, Italy).
Proliferation assay LLC (2 Â 10 6 in T25 flasks) were infected with the recombinant vectors at MOI 2.0. 48 h later, conditioned media were collected and overlaid on HUVECs (3000 cells/well in 96-well flat, collagen-treated plates) at different LLC-conditioned vs standard HUVEC medium ratios. After 5 days, viable HUVECs were quantified by MTT assay.
Migration assay LLC were infected at MOI 2.0 with the recombinant vectors and seeded into the lower compartments of 8.0-mm pore size, six-well transwell inserts (Costar, Milan, Italy), at a density of 8 Â 10 5 cells/well. Forty-eight hours later, bFGF 5 ng/ml was added as a chemotactic stimulus and 1 Â 10 4 HUVEC pretreated with DiI 18 C (1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethyl-indocarbocyanine perchlorate; Fluka, Milan, Italy) fluorescent tracer (5 mg/ml) were plated onto the transwell filters. After a 5 h incubation at 371C and 5% CO 2 , non-migrated cells were scraped off the upper filter surface while the migrated HUVECs were fixed with 4% paraformaldehyde and counted.
Tube formation assay
We used a patented kit consisting of human endothelial and fibroblast cells co-cultured in a 24-well plate (AngioKit; TCS, Buckingham, UK). Cells were infected with recombinant vectors at MOI 1.0 on days 1, 4, 7 and 10 after cell seeding. Positive and negative controls were 2 ng/ml VEGF and 20 mM suramin-treated cells, respectively. On day 11, samples were fixed with ethanol 70% and incubated with a primary anti-CD31 and a secondary AP-conjugated antibody, according to the manufacturer's recommendations. Immunocomplexes were detected by incubation with 5-bromo-4-chloro-3-indolyl phosphate and nitrotetrazolium blue chloride substrates. Tube networks were then photographed; eight fields per slide were randomly chosen to ensure objectivity of sampling. Data were analyzed by NIH ImageJ software (Rasband, WS, ImageJ, US National Institute of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997-2006): images were binarized to black and white and a common threshold was set such that correct vascular morphology was represented with a minimum of background noise. The percentage of black pixels over total field area, representing positive CD31-AP staining, was determined by histogram analysis.
In vivo studies Five-week-old female C57BL/6 immunocompetent mice were purchased from Charles River, Lecco, Italy, housed and maintained in controlled air flow cabinets. Animals were given water and standard chow ad libitum, and were kept on a 12 h light/dark cycle. All animal procedures were performed according to the approved protocols and in compliance with recommendations for proper care and use of laboratory animals.
LLC cells were harvested from subconfluent cultures, washed once in serum-free medium and resuspended in PBS-A. Only suspensions consisting of single cells with at least 90% viability were used for the injections. To induce tumors, 5 Â 10 5 LLC were injected subcutaneously into the left flanks of mice. Three days later, when tumors reached about 50 mm 3 in volume, mice were randomized into five groups (six mice each) subjected to different treatments: T0Z (1 Â 10 6 PFU) with or without GCV; a mixture of 5 Â 10 5 PFU T0endoHangio and 5 Â 10 5 PFU T0endoHkrin-gle5 with or without GCV; PBS-A only. The vectors were administered three times a week, directly into the tumor. GCV (100 mg/kg) was injected daily by intraperitoneal (i.p.) route. Tumor volume was determined by using the equation: (a 2 Â b Â P)/6, where 'a' is the tumor width and 'b' the tumor length. Measurements were performed every other day with a digital calliper by the same operator; each time point represents the mean7s.d. tumor dimensions in each group. The mice were euthanized when their tumors reached 1500 mm 3 in volume or became ulcerated, as per the protocol approved by the University of Ferrara Institutional Animal Care and Use Committee.
For the in vivo tumorigenesis experiments, LLC cells were infected for 1 h in suspension at MOI 1 with the recombinant vectors, washed twice, resuspended in PBS-A at 1Â 10 7 cells/ml and then injected (1 Â 10 6 cells/ mouse) into the left flanks of C57BL/6 mice. GCV was administered i.p. for a week afterwards. Tumorigenesis was evaluated as previously described in this section. Mice that have failed to establish tumors following injection with vector-infected LLC were monitored for about 3 months.
Statistical analysis
All experimental data are expressed as mean7s.d. Statistical significance was assessed using the two-way Non-replicative HSV-1-mediated cancer gene therapy E Berto et al analysis of variance (ANOVA) and Bonferroni post-test for cytotoxicity, proliferation and tumor growth rates. Migration and tube formation were analyzed by one-way ANOVA þ Newman-Keuls post-test. Po0.05 was considered statistically significant.
Results

Construction of T0endoHangio and T0endoHkringle5 vectors
Vectors were constructed by recombination between the plasmids carrying endostatinHkringle5 or endostatinHangiostatin expression cassettes and the UL41 locus of a previously described HSV-1 vector, T0Z, as described in the Material and methods section. T0endoHangio, T0en-doHkringle5 and parental vector T0Z are deficient for the HSV genes encoding infected cell proteins (ICP) 4, 22, 27 and virion host shut-off protein, 25 and have the early promoter of the resident tk gene replaced by the IE ICP4 promoter, which enables the expression of the tk gene as an IE gene ( Figure 1a ). THZ4 vector, which was used as negative control for TK activity assay, contains lacZ gene in place of the resident tk gene, and is thus incapable of TK production.
Expression and biological activity of antiangiogenic proteins and TK Western blot assays were performed on LLC cells infected with the recombinant vectors. Endostatin, angiostatin and kringle5 expression were determined at different time points post-infection by using an endostatin-specific polyclonal antibody. In T0endoHangio and T0endoH kringle5-infected LLC, we observed a robust expression of the transgenes for up to 3 days post-infection both in culture media and in cell lysates, whereas the expression of these proteins was absent in T0Z-infected cells. The angiostatic proteins were detectable in the cell culture media both in the cleaved and in the uncleaved form ( Figure 1b ). The same pattern was observed upon Vero cells infection (data not shown).
We tested the cytotoxic activity of HSV-1 tk suicide gene coexpressed with antiangiogenic factors by our vectors, following cell infection and GCV addition to the cell culture media (Figure 2 ). Results showed a highly significant, time-increasing cytotoxic effect of GCV treatment on both types of cells infected with the TK-expressing vectors (panels a and c). In absence of GCV, there was no toxicity on LLC (panel b), while a cytostatic effect was evident on primary ECs for up to 3 days post-infection (panel d); interestingly, HUVECs infected with the control vectors started to duplicate on the fourth day, whereas the growth inhibition effect on the HUVECs infected with T0endoHangio and T0endoHkringle5 was persistent, presumably owing to the biological effects of the antiangiogenic proteins.
To further investigate the effects of endostatinHangiostatin and endostatinHkringle5 on primary ECs, cell culture media from LLC infected with the recombinant vectors were collected, either diluted with fresh medium at different ratios or not, and overlaid on HUVEC. After a 5 days incubation, HUVEC viability was measured by MTT assay. Representative dose-response curves Non-replicative HSV-1-mediated cancer gene therapy E Berto et al are shown in Figure 3a : the cell culture media obtained from the T0endoHangio and T0endoHkrin-gle5-infected LLC are bioactive and inhibit EC proliferation in a dose-dependent manner, while the medium collected from control vector-infected cells does not. None of the conditioned supernatants influenced the growth of LLC tumor cells at any concentration (data not shown), which is consistent with the previous findings indicating that antiangiogenic factors specifically inhibit the proliferation of endothelial, and not tumor cells.
27-29
We used transwell systems to study the effect of our recombinant vectors on another important aspect of EC biology, that is, their ability to migrate from the upper compartment toward a chemotactic stimulus represented by uninfected or vector-infected LLC þ bFGF in the lower compartment ( Figure 3b) ; the results showed the ability of both vectors expressing angiostatic proteins to reduce the migration of HUVEC toward stimulus, whereas control vector showed no interference at all with their migration competence. The reduction of HUVEC migration was observed when T0endoHangio and T0endoHkringle5 were used either separately or in combination, and these inhibitory effects were statistically significant (Po0.001) in comparison with the positive control (uninfected LLC þ bFGF).
The angiostatic potential of the T0endoHangio and T0endoHkringle5-encoded proteins was further demonstrated on in vitro tubes formation (Figure 3c ). While VEGF-treated control cultures showed numerous sprouts, treatment with T0endoHangio, T0endoHkringle5 and the two vectors together demonstrated a significant drop in the number of end points, branch points and overall vessel length. The infection with control vector resulted in pronounced inhibitory effects on the above parameters too. The small difference between the control vector and the endoHangio and endoHkringle5 recombinants related to the positive control (Figure 3c ) can be most likely due to the temporary stationary non-proliferating condition induced by an HSV vector on primary culture cells that is more evident when we are working in short experimental time conditions with low replicating ECs; we noticed the same effect in the cytotoxicity test performed on HUVEC cells (Figure 2d) . The difference between the T0endoHangio, T0endoHkringle5 and control vectorinfected co-cultures was however statistically significant (Po0.05). Non
Combined antiangiogenic-suicide gene therapy of LLC subcutaneous tumors using T0endoHangio and T0endoHkringle5
The LLC cell line we used was reported to induce highly vascularized tumors in syngeneic mice, and thus represents a stringent test for preclinical models of angiostatic molecules-based antitumor therapy. One of our objectives was to evaluate the possibility to increase the therapeutic potential of the antiangiogenic proteins on pre-established LLC tumors by treating them simultaneously with endostatin-, angiostatin-and kringle5-encoding HSV-1 recombinant vectors. To this purpose, we induced tumor formation by injecting LLC cells subcutaneously into the left flank of C57BL/6 syngeneic mice. When tumors reached about 50 mm 3 in volume, they were treated locally with both T0endoHangio and T0endoHkringle5, or with T0Z vectors. 24 or 48 h after vectors injection GCV was administered i.p. to determine whether combined treatment could inhibit tumor growth more effectively than therapy with angiostatic or TK genes individually. Tumor growth was observed during a 20-day period. Figure 4 shows the data obtained in two similar settings (each repeated twice) in which we maintained the same experimental conditions, except for the starting time of the administration of GCV. Tumor dimensions when GCV injections were started 48 or 24 h after vector inoculation are shown in Figures 4a and b , respectively. Statistical analysis on tumor size data revealed that there were no significant differences between T0endoH angio þ T0endoHkringle5 and T0Z groups when GCV Conditioned cell culture media from uninfected LLC or from LLC infected with the recombinant vectors were overlaid on HUVEC and their viability was evaluated by MTT assay after 5 days at 371C in 5% CO 2 . Each value in the graph is the mean7s.d. of quadruplicate absorbance values measured at 570 nm in two representative experiments. T0endoHangio: black rhombus; T0endoHkringle5: black circle; T0endoHangio þ T0endoHkringle5: black triangle; THZ4: white triangle; non-conditioned HUVEC cells: white square. Proliferation was calculated from the formula: (A/B) Â 100, where A is the absorbance of HUVEC treated with vector-infected LLC supernatants and B the absorbance of non-conditioned HUVEC. At ratio 2:1 of vectorinfected LLC conditioned supernatant over standard HUVEC medium, cellular proliferation was reduced in a significant way (Po0.001) in comparison to non-conditioned HUVEC. Significant differences were also observed between THZ4 control and antiangiogenic vectors (Po0.001 for T0endoHangio þ T0endoHkringle5; Po0.01 for T0endoHkringle5; Po0.05 for T0endoHangio). The HUVEC growth inhibition in presence of T0endoHangio and T0endoHkringle5-infected LLC conditioned media decreased progressively at the increasing of standard medium proportion in the mixture with the conditioned supernatants, showing that the activity of the antiangiogenic proteins was dose-dependent. The inhibitory activity was completely abolished at the 1:100 ratio of conditioned vs standard medium. (b) Inhibition of HUVEC migration toward a chemotactic stimulus. LLC were placed in the lower compartments of six-well transwell systems and infected with the recombinant vectors. Forty-eight hours after infection, 5 ng/ml bFGF was added and HUVEC were placed in the upper chambers; after 5 h incubation, cells that had migrated from the upper to the lower filter surface were fixed and counted. Means for 16 fields of each group were calculated. Results are expressed as percentage of the mean number of migrated cells over uninfected LLC-induced cell migration, which was assumed as 100% of HUVEC migration. Both T0endoHangio and T0endoHkringle5 alone or together were able to significantly inhibit HUVEC migration toward a chemotactic stimulus (Po0.001). (c) Tube formation assay. A mixture of human endothelial and fibroblast cells provided in a patented commercial kit were infected with the vectors on days 1, 4, 7 and 10 after cell seeding. A total of 2 ng/ml VEGF and 20 mM suramin were added as positive and negative controls, respectively; THZ4 was used as viral vector control. On day 11, the cells were incubated with an anti-CD31 antibody, in order to put in evidence and count the tubes that had been formed in each well. The experiment was performed twice. Representative images of tube network of each group are reported in the figure. Eight fields per well were randomly chosen to ensure objectivity of sampling and analyzed by NIH ImageJ software as described in Material and Methods section. Cells treated with antiangiogenic vectors differ significantly from those treated with control vector (Po0.05, indicated with an asterisk in the graph), although the control vector also induces a great inhibition of sprouts (Po0.001 in comparison to positive control). bFGF, basic fibroblast growth factor; HUVEC, human umbilical vein endothelial cells; LLC, Lewis lung carcinoma, MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.
Non-replicative HSV-1-mediated cancer gene therapy E Berto et al administration started 48 h after the vector injection (P40.05). However, tumor growth was considerably inhibited in comparison to the saline-injected and T0Z or T0endoHangio þ T0endoHkringle5-injected groups in absence of GCV (Po0.001). In the second experimental setting, in which the GCV treatment was started 24 h after vector injection, tumor growth was completely arrested and tumor dimensions remained stable in the T0Z-treated group. Surprisingly, the intratumoral treatment with T0endoHangio þ T0endoHkringle5 in presence of GCV did not cause the arrest of tumor growth, although the tumor growth rate was reduced in comparison to the saline-injected (Po0.001) and T0Z or T0endoH angio þ T0endoHkringle5-injected groups in absence of GCV (Po0.001), thus suggesting that there were no advantages of using antiangiogenic þ suicide gene combined approach instead of the suicide gene alone, at least in the treatment of pre-established LLC tumors. For the tumor establishment experiments, we infected in vitro LLC cells with T0endoHangio þ T0endoHkrin-gle5 or T0Z vectors, and then inoculated them subcutaneously into the left flanks of mice. Uninfected cells were injected in the control group. Tumor development was then monitored during a 3-month period. Rapid regression and then the complete disappearance of small palpable tumors that were perceptible from days 4 to 7 was observed in all the mice inoculated with T0endo-Hangio þ T0endoHkringle5-infected LLC, independently of the presence of GCV. The same results were obtained in the mice inoculated with T0Z-infected LLC cells, but only if GCV treatment followed. The mice inoculated with uninfected LLC or with T0Z-infected LLC in absence of GCV developed rapidly growing tumors, and were euthanized when tumor dimensions exceeded 1500 mm 3 ( Figure 5 ).
Discussion
The aims of this work were to study the effect of three antiangiogenic molecules, produced locally by recombinant HSV-1 vectors, on the growth of pre-existing subcutaneous solid LLC tumors and on the in vivo LLC tumor establishment. We also wanted to examine whether a combined antitumor approach, consisting of simultaneous expression of HSV-1 tk suicide and angiostatic genes, could be more efficient, in a solid tumor model, in comparison with the antiangiogenic or the suicide gene treatment alone. We chose the LLC cells as a model because of their capacity to form highly vascularized and rapidly growing solid tumors in syngeneic C57BL/6 mice. The local delivery of the therapeutic molecules was achieved by using replication defective HSV-1-based vectors encoding two different fusion antiangiogenic proteins of human origin, endostatinHangiostatin and endostatinHkringle5 (Figure 1a ). Both these vectors express the autologous tk suicide gene, which can be a b Figure 4 Activity of HSV-1-based vectors on LLC tumor growth. C57BL/6 mice were injected subcutaneously with 5 Â 10 5 LLC and treated with antiangiogenic and suicide gene expressing vectors three times a week, starting from the third day. The prodrug GCV was injected daily by intraperitoneal route 48 h (a) or 24 h (b) after the first vector injection. Tumor volumes were measured every other day; each time point represents the mean7s.d. of six mice in each group. PBS-A group: white square; T0Z group: white triangle; T0Z þ GCV group: X; T0endoHan-gio þ T0endoHkringle5 group: white circle; T0endoHangio þ T0endoHkringle5 þ GCV group: black circle. (a) There were no significant differences between T0endoHangio þ T0endoHkringle5 and T0Z groups when GCV administration started 48 h after the vector injection (P40.05). However, the tumor growth was considerably inhibited in both of these groups in comparison to the saline-injected and T0Z or T0endoHangio þ T0endoHkringle5-injected groups in absence of GCV (Po0.001). (b) When the GCV treatment started 24 h after vector injection, the tumor growth was completely arrested and the tumor dimensions remained constant in the T0Z-treated group. The intratumoral treatment with T0endoHangio þ T0endoHkringle5 in presence of GCV did not cause the tumor growth arrest, although the tumor growth rate was reduced in comparison to the saline-injected (Po0.05) and T0Z or T0endoHangio þ T0endoHkringle5-injected groups in absence of GCV (Po0.001). Apparently, there were no advantages of using antiangiogenic þ suicide gene combined approach instead of the suicide gene alone, at least in the treatment of pre-established LLC tumors. GCV, ganciclovir; LLC, Lewis lung carcinoma.
Non-replicative HSV-1-mediated cancer gene therapy E Berto et al activated by the GCV prodrug administration. The advantages of cloning transgenes in separate cassettes of the same vector instead of their expression by bicistronic messengers is that the transgene-encoded protein levels can be both elevated and comparable between them, which is usually not achievable by using IRES sequences. Moreover, the combination of multiple exogenous genes in a unique vector enables their simultaneous expression in the transduced cells, which is not the case if different vectors are used to deliver two or more transgenes.
The western blot experiments showed that the antiangiogenic genes were expressed in vitro by LLC cells at high levels under the control of a strong promoter of heterologous (HCMV IEp) origin for up to 2 days (Figure 1b) . The HSV TK expression, guided by the autologous ICP4 IE promoter, was demonstrated by performing cytotoxicity assays in presence of the prodrug GCV (Figures 2 a and c) .
To evaluate the biological activity of the vectorexpressed angiostatic proteins, we performed several in vitro assays, including EC proliferation, migration and differentiation, all of which play a dynamic role in angiogenesis, both in physiological and pathological conditions. We demonstrated that angiostatic proteins, released in the cell culture media by T0endoHangio and T0endoHkringle5 infected LLC cells, were highly efficient in inhibiting HUVEC proliferation and migration. EndostatinHkringle5-containing media were more efficient in inhibiting HUVEC proliferation than those containing endostatinHangiostatin (Figure 3a ), but the two had comparable antimigratory activity (Figure 3b) . Finally, we performed in vitro tube formation assays, which reflect the net contribution of cell migration, proliferation and survival to the creation of primitive blood vessels. 1 These assays, involving primary ECs and fibroblasts infected with the T0endoHangio and T0en-doHkringle5 or with the control vector, showed that the angiostatic proteins, alone or in combination, were capable of reducing the density, the dimensions and also the number of ramifications of the tubes (Figure 3c ).
After the encouraging results obtained in vitro, we performed in vivo experiments in a murine preclinical model. We tested the effect of recombinant HSV-1-based vectors on the growth of pre-existing solid LLC tumors and on the LLC tumor establishment.
We induced subcutaneous solid LLC tumors in C57BL/ 6 mice to test the possibility of enhancing the therapeutic effect of three different antiangiogenic molecules, delivered simultaneously in situ by our recombinant vectors, on tumor growth. The intratumoral injection of T0en-doHangio þ T0endoHkringle5 vectors in absence of GCV treatment was not capable of reducing the pre-established tumor growth rate. This observation might suggest that the antitumor effect of these three angiostatic proteins, as far as highly aggressive and vascularized tumors like LLC are concerned, is restricted to the phase of tumor establishment, characterized by the assemblage of new blood vessels by ECs. In a similar way, only a slightly inhibitory activity of angiostatin or endostatin-expressing adenoviral vectors was reported by Kuo et al. 30 on the growth of pre-established LLC tumors. Another possible explanation for the inefficiency of the combination of endostatin, angiostatin and kringle5 delivered by our vectors to pre-established tumors might be that the in vivo expression of the proteins, although very high in vitro, could still not be sufficient to achieve significant inhibitory effects. In addition, the diffusion of recombinant vectors delivered by intratumoral injections is likely to be hampered by the tumor stroma or by the high intratumoral pressure, caused by leaky structure of tumorassociated vessels. Furthermore, direct observations of tumor morphology suggest the capacity of the LLC tumor cells to mimic and partially substitute the ECs in the formation of intratumoral blood capillaries (G Altavilla, personal communication). This phenomenon, termed vasculogenic mimicry, does not seem to be sensitive to endostatin activity, 31 and we hypothesize that it might be in part responsible for the lack of LLC tumor growth inhibition by our antiangiogenic vectors. In addition to angiogenesis, there have been suggestions that vasculogenesis may also contribute to neovascularization of LLC tumors. 32 In contrast to neoangiogenesis, the hallmark of 6 cells in 100 ml for each mouse) and injected into the left flanks of C57BL/6 mice. GCV (100 mg/kg) was administered i.p. for a week afterwards to one-half of each group. Tumor volumes were measured with a digital calliper every other day; each time point represents the mean7s.d. of six mice. Uninfected LLC: white square; T0Z-infected LLC: white triangle; T0Z-infected LLC þ GCV treatment: X; T0endoHan-gio þ T0endoHkringle5-infected LLC: white circle; T0endoHan-gio þ T0endoHkringle5-infected LLC þ GCV treatment: black circle. LLC infected with T0-endoHangio þ T0-endoHkringle5 were incapable of establishing tumors in mice either treated with GCV or not. T0Z-infected cells failed in establishing tumors as well, but only when mice were treated with GCV. Surviving animals were monitored throughout a 3-month period, during which no sign of tumor growth was observed. GCV, ganciclovir; LLC, Lewis lung carcinoma; MOI, multiplicity of infection.
Non-replicative HSV-1-mediated cancer gene therapy E Berto et al vasculogenesis is the formation of vessels de novo by infiltration of tumor site and assembly of endothelial CD34 þ precursor cells into functional blood vessels. Based on the available evidence, mobilization and functional incorporation of circulating endothelial precursor cells into the tumor vasculature is essential for the growth of lymphomas, LLCs and colon cancers. It is therefore likely that an efficient antivascular strategy, at least in the pre-established LLC tumor model, should comprise molecules capable of contrasting not only tumor-induced neoangiogenesis but also vasculogenesis and vasculogenic mimicry.
In contrast with the lack of growth inhibitory effect of T0endoHangio þ T0endoHkringle5 in absence of GCV, when tumor masses were treated with T0endoHangio þ T0endoHkringle5 or with T0Z control vector followed by GCV i.p. injections 48 h later, we observed a statistically significant reduction in tumor growth rate in comparison to saline-or vector-injected but GCV-untreated mice. When we started the GCV administration 24 h after vector injection, we observed tumor shrinkage first and then complete growth arrest when we used TK-expressing control vector. The difference in the tumor inhibitory activity of the same vector might be due to the difference in the tumor size at 24 and 48 h after their becoming palpable. The tumor mass is smaller at 24 h and its cells should thus be easier to transduce by the recombinant vector expressing the TK suicide gene. Moreover, the TK/GCV-associated bystander effect is likely to work better under these conditions than inside the larger tumors with more dense and compact structure. Surprisingly, in the same conditions the intratumoral injections with T0endoHangio þ T0endoHkringle5 were only able to reduce the tumor growth rate, but not to abolish it. Apparently, the antiangiogenic proteins did not synergize with TK/GCV system in our experimental tumor model, and seemed to actually counteract the suicide gene activity. A possible explanation for this fact might be the observation, reported by Teicher 33 and then Jain 34 that antiangiogenic factors actually stabilize tumorassociated blood vessels thus improving their structural and functional characteristics at the beginning of their administration. The stabilization of tumor vessels leads to a more efficient oxygenation and nutrition of its tissue. We hypothesize that the tumor vessel-stabilizing activity had made it possible for the tumor to outgrow the size that was efficiently contrasted with the TK/GCV alone. We cannot however exclude that a more prolonged treatment with both angiostatic proteins and TK/GCV system might ultimately result in tumor shrinkage or at least in its growth arrest. Previously published data seem to support the need for prolonged administration of antiangiogenic agents to achieve the tumor reduction or its stabilization at a certain level. 11 The second aim of the present study was to assess the therapeutic activity of our recombinant vectors on the LLC tumor establishment. To study their effect on the capacity of the LLC cells to originate tumors in vivo, we infected these cells in vitro with T0endoHangio and T0endoHkringle5 or with the control vector, and then injected them subcutaneously into C57BL/6 mice flanks. The LLC cells infected with T0endoHangio þ T0-endoHkringle5 originated small palpable masses of p40 mm 3 by day 4, which decreased in size thereafter and completely disappeared by day 10 in 100% of the mice. The follow-up period of 3 months showed that there were no tumor recurrences either at the primary sites of tumor cells injection or at distant sites and organs. The results were identical either in presence or in absence of i.p. GCV administration to mice. The comparison of our experiments with those performed by Li et al. 35 who reported a 50% establishment inhibition in the same tumor model utilizing an adenoviral vector encoding a single angiogenesis inhibitor (tissue inhibitor of matrix metalloproteinase), might suggest the superiority of the combination of multiple antiangiogenic proteins in contrasting the LLC tumor formation. We were also able to abolish the LLC tumor establishment by preinfecting the cells with the control vector expressing the TK gene and not the antiangiogenic proteins, but only if GCV was administered. Control mice inoculated with uninfected LLC cells and T0Z-infected cells in absence of GCV treatment originated rapidly growing tumors, and were euthanized by day 20. Taken together, our data suggest that LLC tumor establishment can be achieved by injecting T0-endoHangio and T0-endoHkringle5-infected LLC cells into C57BL/6 mice, owing to the secretion of angiostatic molecules in the local microenvironment. Moreover, no differences were observed between GCVtreated and untreated mice. Tumor establishment inhibition can also be accomplished by injecting T0Z-infected LLC cells into mice, but only in presence of GCV. We hypothesize that the tumor establishment inhibitory activity of the TK/GCV system might depend on the fact that it is capable of killing, owing to the bystander effect, not only vector-transduced but also neighboring cells of both tumor and perhaps endothelial origin, when these reach the tumor site attracted by tumor-released chemotactic stimuli. Both tumor and ECs were shown to be highly susceptible to the activity of the TK enzyme and its prodrug in the in vitro experiments (Figure 2) , and we thus think that the same might have occurred in vivo, too. Furthermore, the induction of tumor-specific immune response by TK/GCV treatment was previously reported in the literature, 36 and therefore we cannot exclude the possibility that the immune response against LLCassociated antigens might contribute to the overall TK/ GCV antitumor activity in our experimental model.
Taken together, our data provide experimental evidence for the use of recombinant replication-defective HSV-1 vectors in solid tumor treatment. The expression of autologous TK gene in association with GCV was shown to be highly efficient in both reducing small tumor masses growth rates and also in inhibiting tumor cell engraftment. The expression by tumor cells of vectorencoded angiostatic proteins was also extremely efficient in inhibiting the tumor establishment, both in presence and in absence of GCV. The wide spectrum of dividing or non-dividing cell types that can be easily infected by nonreplicative HSV-1 vectors, and among them endothelial and dendritic cells, along with their large exogenous DNA accommodating capacity, makes these vectors very attractive delivery systems. These unique features might be of extreme importance for combined therapeutic strategies requiring the simultaneous expression of high levels of multiple foreign genes, like suicide genes, cytokines or other immunomodulatory molecules, antiangiogenic proteins, soluble growth factor receptors and so forth. As various types of tumors present different characteristics, the high manageability of large, wellcharacterized HSV-1 genome might permit the combination, in a unique backbone, of the most appropriate exogenous genes for treatment of each particular tumor.
